ANSWER: B

Rationale:

The primary mechanism by which statins increase hepatic LDL receptor expression is a well-characterized sterol-sensing feedback loop. HMG-CoA reductase inhibition reduces intracellular free cholesterol in hepatocytes below a threshold sensed by SCAP (SREBP cleavage-activating protein). When cholesterol is replete, SCAP holds the SCAP-SREBP-2 complex in the ER through INSIG (insulin-induced gene) retention proteins. As cholesterol falls, INSIG releases the SCAP-SREBP-2 complex, which traffics to the Golgi where Site-1 and Site-2 proteases cleave SREBP-2, releasing its active N-terminal transcription factor domain. This fragment translocates to the nucleus and binds sterol response elements (SREs) in the promoters of both HMG-CoA reductase (a partially compensatory response) and, critically, the LDL receptor gene. The resulting increase in LDL receptor surface density dramatically accelerates hepatic clearance of LDL, IDL, VLDL remnants, and Lp(a) -- this receptor-mediated clearance is the dominant mechanism of plasma LDL-C lowering by statins. Option A: LXR activation by statins is pharmacologically incorrect. LXR is activated by oxysterol ligands and promotes cholesterol efflux and reverse transport -- it is not the transducer of statin-induced LDL receptor upregulation. LXR actually downregulates LDL receptor in some contexts by upregulating IDOL (an E3 ubiquitin ligase that degrades LDL receptors). Option B: Correct. The SCAP-SREBP-2-INSIG pathway is the established molecular mechanism coupling statin-induced intracellular cholesterol depletion to LDL receptor transcriptional upregulation and increased hepatic LDL clearance. Option C: MTP inhibition is the mechanism of lomitapide, approved for homozygous familial hypercholesterolemia (HoFH). Statins do not inhibit MTP. While statins modestly reduce VLDL secretion as a secondary effect of reduced hepatic cholesterol availability, this is not the mechanism of LDL receptor upregulation. Option D: Statins have no direct molecular interaction with the LDL receptor protein. Their effect on LDL receptor is entirely transcriptional -- increasing receptor number, not receptor affinity for apolipoprotein B-100. Option E: Farnesyl pyrophosphate depletion is relevant to statin pleiotropic effects (prenylation of Rho GTPases), but reduced Rho GTPase prenylation impairs -- not activates -- Rho signaling. Rho GTPase does not directly upregulate LDL receptor transcription; that pathway is SREBP-2-dependent.

ANSWER: D

Rationale:

The statin dose-response curve is log-linear, not linear -- meaning that each doubling of the dose produces approximately 6% additional absolute LDL-C reduction regardless of the starting point. This is the rule of 6s. Going from atorvastatin 40 mg to 80 mg would be expected to reduce LDL-C by approximately an additional 6 percentage points in absolute terms -- insufficient to close a meaningful gap to target in many patients. Two mechanisms underlie this plateau: first, compensatory upregulation of HMG-CoA reductase gene expression itself (co-induced by SREBP-2 along with LDL receptor) partially restores enzyme activity despite inhibition; second, statins co-induce PCSK9 transcription through SREBP-2, increasing LDL receptor degradation and partially attenuating the gains in receptor surface density. The clinical implication is direct: when a patient on moderate-intensity statin therapy has not reached LDL-C target, adding ezetimibe or a PCSK9 inhibitor -- each providing an independent mechanism of LDL-C lowering -- is pharmacologically more efficient than escalating the statin dose against the same log-linear plateau. Option A: A 25-30% additional absolute LDL-C reduction from dose doubling would require a linear dose-response curve. Clinical trial data comparing moderate-intensity to high-intensity statin therapy consistently show approximately 6% additional absolute LDL-C reduction with each dose doubling, not 25-30%. Option B: HMG-CoA reductase inhibition does not follow simple linear first-order kinetics at clinical doses. The dose-response curve is log-linear. Compensatory feedback responses -- including HMG-CoA reductase upregulation and PCSK9 co-induction -- prevent proportional LDL-C reductions with proportional dose increases. Option C: HMG-CoA reductase is not fully saturated at moderate statin doses -- significant residual enzyme activity remains, which is why dose escalation produces any additional LDL-C reduction at all. The approximately 6% rule is not "negligible," but it is modest, and it does not arise from extrahepatic effects. Option D: Correct. The rule of 6s describes the log-linear statin dose-response curve; approximately 6% additional absolute LDL-C reduction per dose doubling results from compensatory HMG-CoA reductase upregulation and PCSK9 co-induction through SREBP-2. Option E: Statins do not suppress intestinal cholesterol absorption to a clinically meaningful degree. Intestinal absorption inhibition is the mechanism of ezetimibe, which blocks NPC1L1 (Niemann-Pick C1-Like 1 protein). This option incorrectly attributes an ezetimibe mechanism to high-dose statin therapy.

ANSWER: A

Rationale:

Diltiazem is a moderate CYP3A4 inhibitor. Statins that rely on CYP3A4 for metabolism -- principally simvastatin and atorvastatin -- are subject to elevated plasma concentrations when CYP3A4 is inhibited, increasing exposure in skeletal muscle and raising the risk of statin-associated muscle symptoms (SAMS), including myopathy and, rarely, rhabdomyolysis. Rosuvastatin is the safest choice in this clinical context because it is not a CYP3A4 substrate. Rosuvastatin undergoes minimal hepatic CYP metabolism (approximately 10% via CYP2C9) and is handled primarily through active OATP1B1-mediated hepatic uptake and biliary elimination. Diltiazem's CYP3A4 inhibition has no meaningful effect on rosuvastatin plasma concentrations, and the risk of SAMS is not potentiated by concurrent diltiazem. Pravastatin is a reasonable alternative for the same reason -- it is minimally CYP-metabolized -- but rosuvastatin provides superior LDL-C lowering at standard doses and is the preferred choice when both efficacy and interaction avoidance are priorities. Option A: Correct. Rosuvastatin's independence from CYP3A4 metabolism means that diltiazem's CYP3A4 inhibitory effect does not raise rosuvastatin exposure, making it the pharmacokinetically safe choice in patients on CYP3A4-inhibiting drugs. Option B: Atorvastatin is a CYP3A4 substrate, and diltiazem does raise atorvastatin plasma concentrations. While the interaction is less severe than with simvastatin (because atorvastatin's active metabolites are also effective, and the interaction is moderate rather than severe at standard doses), atorvastatin is not the preferred choice for avoiding the interaction. The claim that active metabolites compensate and make the interaction negligible overstates the safety of this combination. Option C: Simvastatin is among the statins most severely affected by CYP3A4 inhibition because it is an inactive lactone prodrug requiring hydrolysis, and its primary metabolic pathway is CYP3A4-mediated. Even a moderate CYP3A4 inhibitor such as diltiazem raises simvastatin acid concentrations substantially; the combination carries black-box warning language regarding myopathy risk. This option incorrectly claims first-pass extraction protects against the interaction. Option D: Pravastatin does not undergo CYP3A4 sulfation in the intestinal wall -- this mechanism is fabricated. Pravastatin is minimally metabolized by CYP enzymes overall and does not interact with diltiazem through CYP3A4. The rationale in this option is pharmacologically incorrect even though pravastatin is genuinely a low-interaction statin. Option E: Diltiazem is a CYP3A4 inhibitor, not a CYP2C9 inhibitor of clinical significance. Fluvastatin is indeed metabolized primarily by CYP2C9, not CYP3A4, so diltiazem would have minimal effect on fluvastatin exposure. However, the claim that diltiazem inhibits CYP2C9 more potently than CYP3A4 is pharmacologically incorrect -- diltiazem's primary inhibitory action is on CYP3A4.

ANSWER: C

Rationale:

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted by hepatocytes that binds the LDL receptor extracellular domain in the trans-Golgi network and on the hepatocyte surface, redirecting receptor-ligand complexes to lysosomal degradation rather than allowing receptor recycling after endocytosis. The critical pharmacological interaction is that PCSK9 is co-transcribed by SREBP-2 -- the same nuclear transcription factor that statins activate to upregulate LDL receptor expression. When statins reduce intracellular cholesterol and activate SREBP-2, they simultaneously upregulate both LDL receptor and PCSK9. The resulting increase in PCSK9 production accelerates LDL receptor degradation, partially offsetting the transcriptional increase in receptor expression. This PCSK9 counter-regulation is the mechanistic rationale for PCSK9 inhibitors as add-on therapy to statins: by blocking PCSK9-mediated receptor degradation, PCSK9 inhibitors remove the counter-regulatory brake on LDL receptor density, producing additive LDL-C lowering far greater than statin dose escalation alone can achieve. Option A: HMG-CoA reductase co-induction by SREBP-2 is real and does partially counteract statin efficacy. However, this does not cause INSIG to re-engage SCAP-SREBP-2 and return LDL receptor transcription to pre-treatment levels within 72 hours. A new partial steady state is reached, but LDL receptor expression remains meaningfully elevated above pre-treatment baseline throughout statin therapy. The 72-hour reversal described is pharmacologically incorrect. Option B: Farnesoid X receptor (FXR) is activated by bile acids, not by farnesyl pyrophosphate. Statins do reduce farnesyl pyrophosphate, but this does not activate FXR. IDOL is a real E3 ubiquitin ligase that degrades LDL receptors (through a distinct mechanism from PCSK9), but its induction is driven by LXR activation, not FXR. The mechanism described is pharmacologically fabricated. Option C: Correct. SREBP-2 co-transcribes both LDL receptor and PCSK9; statin-induced SREBP-2 activation therefore simultaneously increases LDL receptor production and PCSK9 production. Increased PCSK9 promotes lysosomal degradation of LDL receptors, partially offsetting receptor expression gains -- explaining why statins do not achieve LDL-C reductions greater than approximately 50-60% at maximum doses. Option D: While statins have modest effects on apolipoprotein C-III (apoC-III) in some studies, reduction of apoC-III is not an established statin mechanism and does not produce a counter-regulatory effect restoring plasma LDL-C. The described pathway is not a recognized pharmacological consequence of statin therapy. Option E: Statin-induced depletion of geranylgeranyl pyrophosphate does impair Rab GTPase prenylation and can affect vesicle trafficking -- this is pharmacologically real in the pleiotropic effects literature. However, this is not an established mechanism limiting LDL receptor surface density in hepatocytes at clinical statin doses. The counter-regulatory mechanism limiting statin efficacy is PCSK9 co-induction, not Rab GTPase-mediated trafficking impairment.

ANSWER: E

Rationale:

The Cholesterol Treatment Trialists (CTT) Collaboration meta-analysis -- with the most comprehensive update published in 2010 in The Lancet -- pooled individual patient data from 26 randomized statin trials involving 169,138 participants. The central finding was that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C produces a proportional 22% reduction in major vascular events (non-fatal myocardial infarction, coronary death, coronary revascularization, and stroke). This relationship held across baseline LDL-C levels, age, sex, diabetes status, blood pressure, and prior cardiovascular disease -- confirming that LDL-C reduction itself, rather than any statin-specific or pleiotropic mechanism, is the primary driver of clinical benefit. Because the proportional risk reduction is constant, absolute benefit scales with baseline cardiovascular risk: a patient at higher absolute risk derives greater absolute event reduction from the same proportional risk reduction. Option A: The CTT Collaboration 2010 update included 26 trials and approximately 169,000 participants -- not 14 trials and 87,000 participants. The 35% figure is also incorrect; the established finding is 22% per mmol/L. The restriction of benefit to patients with baseline LDL-C above 3.0 mmol/L is incorrect -- the CTT analysis demonstrated benefit across all baseline LDL-C levels. Option B: The CTT meta-analysis does not conclude that pleiotropic effects dominate statin clinical benefit. On the contrary, its finding that event reduction scales precisely and proportionally with the magnitude of LDL-C lowering -- across all statins and all doses -- is the strongest evidence that LDL-C reduction itself is the dominant mechanism. Option C: The CTT Collaboration demonstrated event reduction in both secondary and primary prevention populations. The 22% per mmol/L LDL-C reduction was not restricted to secondary prevention; benefit in primary prevention patients was statistically significant in the pooled dataset, though absolute benefit is smaller due to lower baseline risk. Option D: The CTT meta-analysis explicitly found that the proportional risk reduction per unit LDL-C lowering was consistent across different statins -- it did not differ significantly between rosuvastatin, simvastatin, atorvastatin, or pravastatin when LDL-C lowering was equivalent. This is precisely the evidence that benefit is driven by LDL-C reduction rather than statin-specific mechanisms. Option E: Correct. The CTT Collaboration pooled 26 trials, approximately 169,000 participants, and established the 22% proportional reduction in major vascular events per 1 mmol/L LDL-C reduction -- a consistent relationship confirming LDL-C lowering as the primary driver of statin benefit.

ANSWER: B

Rationale:

The JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial was specifically designed to test whether statins reduce cardiovascular events in patients who would not traditionally qualify for therapy based on LDL-C alone. Enrollment required LDL-C below 130 mg/dL (mean approximately 108 mg/dL) and hsCRP at or above 2.0 mg/L -- selecting patients with evidence of systemic inflammation without overt dyslipidemia. Rosuvastatin 20 mg daily reduced the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina, or arterial revascularization) by approximately 44% relative to placebo and reduced hsCRP by approximately 37%. The trial raised an important pharmacological question: because patients were enrolled on the basis of inflammation rather than elevated LDL-C, and because both LDL-C and hsCRP fell on treatment, it is difficult to separate the contributions of LDL-C lowering from anti-inflammatory pleiotropic effects to the observed event reduction. The CTT meta-analysis framework would predict substantial benefit from the approximately 50% LDL-C reduction achieved in JUPITER even from this lower baseline -- and the relative contributions of LDL-C lowering versus anti-inflammatory effects remain debated. Option A: The Heart Protection Study (HPS) enrolled patients based on high cardiovascular risk with total cholesterol above 3.5 mmol/L -- not on the basis of elevated hsCRP. Its primary contribution was demonstrating statin benefit independent of baseline LDL-C level, not hsCRP-guided selection. Option B: Correct. JUPITER enrolled patients with LDL-C below 130 mg/dL and hsCRP at or above 2.0 mg/L, and rosuvastatin 20 mg reduced the primary cardiovascular composite endpoint by approximately 44% -- raising the question of whether anti-inflammatory statin effects contribute to benefit beyond LDL-C lowering in this inflammatory-biomarker-selected population. Option C: The TNT trial enrolled patients with stable coronary artery disease (secondary prevention) and compared atorvastatin 80 mg versus 10 mg. Its primary contribution was establishing the incremental benefit of high-intensity over moderate-intensity statin therapy in stable CAD. TNT did not use hsCRP as an enrollment criterion. Option D: The 4S trial enrolled patients with prior coronary heart disease and total cholesterol between 5.5 and 8.0 mmol/L -- a dyslipidemia-based secondary prevention population. hsCRP was not a defining inclusion criterion for 4S. Option E: FOURIER enrolled patients with established atherosclerotic cardiovascular disease on optimized background statin therapy -- it was not a primary prevention trial and did not use hsCRP as an enrollment criterion. Evolocumab was the study drug, not a statin. The description is factually incorrect on multiple points.

ANSWER: A

Rationale:

The anti-inflammatory pleiotropic effects of statins arise primarily from depletion of non-sterol isoprenoid intermediates downstream of HMG-CoA reductase in the mevalonate pathway -- specifically geranylgeranyl pyrophosphate (GGPP). GGPP is required for the post-translational prenylation of small GTP-binding proteins of the Rho family (including RhoA, Rac1, and Cdc42). Prenylation is required for membrane anchoring and activation of Rho GTPases. When GGPP is depleted by statin therapy, Rho GTPases remain unprenylated, cytosolic, and inactive. Because Rho-kinase (ROCK) signaling downstream of RhoA normally promotes NF-kB activation in endothelial cells and macrophages, Rho inactivation reduces NF-kB-driven transcription of pro-inflammatory cytokines (including IL-6, TNF-alpha), adhesion molecules (ICAM-1, VCAM-1), and monocyte chemoattractant proteins. This anti-inflammatory effect is detectable within days of statin initiation -- well before meaningful LDL-C reduction -- consistent with a mechanism independent of cholesterol lowering. Option A: Correct. GGPP depletion impairs Rho GTPase prenylation, reducing membrane anchoring and ROCK-mediated NF-kB activation, which decreases pro-inflammatory cytokine and adhesion molecule expression in endothelial cells and macrophages independently of LDL-C changes. Option B: Statins do not directly bind or inhibit the IKK complex. Their anti-inflammatory effect is indirect, mediated through isoprenoid depletion and impaired GTPase prenylation -- not through direct enzymatic inhibition of NF-kB pathway components. No direct statin-IKK interaction has been established at pharmacological concentrations. Option C: While Ras GTPase prenylation requires farnesyl pyrophosphate (FPP), and statin-induced FPP depletion can affect Ras signaling, T-cell lymphocyte reprogramming toward a Th2 phenotype is not the established primary source of reduced circulating IL-6 and hsCRP with statin therapy. The dominant anti-inflammatory effect is at the level of vascular endothelium and macrophages through Rho GTPase/NF-kB. Option D: Statins do not inhibit COX-2 (cyclooxygenase-2). COX inhibition is the mechanism of NSAIDs and aspirin. Statins and NSAIDs are structurally dissimilar, and statins do not reduce prostaglandin or thromboxane synthesis through COX inhibition. Option E: While PPAR-gamma activation has anti-inflammatory effects and statins have been reported to modestly upregulate PPAR-gamma in some cell types, this is not the primary or established mechanism of statin anti-inflammatory pleiotropy. The dominant mechanism identified in the pharmacological literature is Rho GTPase prenylation inhibition through GGPP depletion, not PPAR-gamma-mediated coactivator competition.

ANSWER: D

Rationale:

The PROVE IT-TIMI 22 trial is the definitive evidence base for high-intensity statin therapy in ACS. The trial enrolled 4,162 patients with ACS (acute myocardial infarction or high-risk unstable angina) within 10 days of presentation and randomized them to atorvastatin 80 mg or pravastatin 40 mg daily, with a median follow-up of approximately 2 years. Atorvastatin 80 mg achieved a median LDL-C of 62 mg/dL compared with 95 mg/dL in the pravastatin arm. The primary composite endpoint (all-cause mortality, myocardial infarction, unstable angina requiring hospitalization, revascularization, and stroke) was reduced by 16% with atorvastatin versus pravastatin. Notably, event curve separation was apparent as early as 30 days, consistent with the rapid pleiotropic benefits of statins -- anti-inflammatory, plaque-stabilizing, and endothelial effects -- acting before substantial LDL-C-mediated plaque remodeling could occur. For this patient -- currently on pravastatin 40 mg with LDL-C of 88 mg/dL presenting with NSTEMI -- the direct clinical implication of PROVE IT is that his statin should be escalated to high-intensity (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) regardless of his current LDL-C, because the ACS event mandates the most intensive available lipid-lowering approach. Option A: The 4S trial enrolled patients with established coronary heart disease and hypercholesterolemia -- it was a secondary prevention trial, not an acute ACS intervention trial. 4S enrolled patients 6 months to 5 years after MI, not within 24 hours of presentation. Option B: HPS was a secondary prevention trial enrolling patients with prior vascular disease -- it was not an ACS trial with 48-hour enrollment. The claim that ACS patients on moderate therapy do not require dose escalation if LDL-C is below 100 mg/dL directly contradicts PROVE IT and current guidelines. Option C: TNT compared atorvastatin 80 mg versus atorvastatin 10 mg in patients with stable coronary disease -- it was not an ACS trial, and it did not compare atorvastatin to rosuvastatin. OATP2B1 is not the mechanism explaining atorvastatin's ACS benefit. Option D: Correct. PROVE IT-TIMI 22 established that high-intensity atorvastatin 80 mg reduces the primary ACS composite endpoint by 16% versus pravastatin 40 mg over approximately 2 years, with early event curve separation and median LDL-C of 62 mg/dL versus 95 mg/dL -- making high-intensity statin therapy the standard of care in all ACS patients. Option E: FOURIER enrolled patients with established atherosclerotic cardiovascular disease on optimized background statin -- it was not an acute ACS intervention trial with 48-hour enrollment. PCSK9 inhibition is not the preferred first-line escalation strategy replacing statin dose escalation in all ACS patients.

ANSWER: C

Rationale:

Statin discontinuation in patients with established ASCVD is associated with increased cardiovascular event risk through two mechanistically distinct processes. The first operates rapidly -- within days to weeks -- as the pleiotropic biological effects of statins dissipate in proportion to the drug's plasma half-life. The anti-inflammatory effects (Rho GTPase prenylation inhibition, NF-kB suppression, reduced macrophage activity within vulnerable plaques), the eNOS upregulatory effect, and the fibrous cap-stabilizing effects of high-intensity statin therapy are all pharmacologically active only while therapeutic statin concentrations are maintained. Their loss removes active biological protection from potentially vulnerable atherosclerotic plaques before any other protective adaptation can occur. The second mechanism operates over a slightly longer timescale: as statin therapy is withdrawn, intracellular hepatic free cholesterol rises, reactivating INSIG retention of SCAP-SREBP-2 and reducing SREBP-2 nuclear activity. Because PCSK9 and LDL receptor are co-transcribed by SREBP-2, both initially fall -- but PCSK9 levels recover relatively promptly as residual statin clears, while LDL receptor synthesis lags, creating a transient period of elevated PCSK9 activity relative to LDL receptor density. This temporarily accelerates LDL receptor lysosomal degradation, reducing hepatic LDL clearance before new receptor synthesis catches up. Population-based studies consistently show elevated rates of recurrent MI and death in patients who discontinue statin after MI, even after confounder adjustment. Option A: NPC1L1 upregulation does not produce a hypercholesterolemia overshoot following statin withdrawal. Intestinal cholesterol absorption returns to baseline as statin concentrations fall but does not exceed pre-treatment levels through an NPC1L1 upregulation mechanism. This is pharmacologically unsupported. Option B: Statins are CYP3A4 substrates, not inhibitors -- discontinuation does not eliminate CYP3A4 substrate competition in any clinically meaningful way. The premise that bile acid precursors accumulate and activate FXR to drive VLDL overproduction within 48 hours of statin withdrawal is pharmacologically fabricated. Option C: Correct. Two temporally distinct mechanisms contribute to the vulnerable period following statin discontinuation: rapid loss of pleiotropic plaque-stabilizing and anti-inflammatory effects, and a transient PCSK9-mediated reduction in LDL receptor surface density as cholesterol homeostasis is re-established after withdrawal. Option D: This option inverts the biology. When statin is discontinued, intracellular hepatic cholesterol rises, which increases INSIG engagement of SCAP-SREBP-2 -- reducing SREBP-2 activity and consequently reducing both HMG-CoA reductase and LDL receptor transcription. A post-discontinuation low-risk period driven by a transient LDL receptor upswing is pharmacologically incorrect and clinically dangerous. Option E: The protection provided by statin pleiotropic effects is not sustained for 90 days after discontinuation. eNOS expression and Rho GTPase-dependent anti-inflammatory effects are pharmacologically active only while statin concentrations are maintained -- they are not stored in long-lived protein pools with 90-day half-lives. The claim that pleiotropic protection persists beyond drug washout is inconsistent with mechanistic evidence.

ANSWER: E

Rationale:

OATP1B1 (organic anion-transporting polypeptide 1B1), encoded by the SLCO1B1 gene, is an influx transporter expressed on the sinusoidal membrane of hepatocytes. Its primary function is the active uptake of statin acid forms from portal blood into hepatocytes -- a process that both concentrates statins at their site of action (the liver) and removes them from systemic circulation, limiting skeletal muscle exposure. The SLCO1B1 c.521T>C variant (rs4149056) is a well-characterized loss-of-function polymorphism that reduces OATP1B1 transport capacity. In carriers -- particularly homozygotes -- hepatic uptake of statins (especially simvastatin acid) is impaired, resulting in a larger fraction of the absorbed dose remaining in systemic circulation. This elevated systemic exposure increases passive diffusion of statin into skeletal muscle, raising the risk of statin-associated muscle symptoms (SAMS) and, in severe cases, rhabdomyolysis. Simvastatin is the most markedly affected agent because it is highly dependent on OATP1B1 for hepatic first-pass extraction. Rosuvastatin and pravastatin -- both hydrophilic agents that depend less on passive membrane diffusion for skeletal muscle entry -- show substantially lower OATP1B1-dependent myopathy risk and are the pharmacogenomically informed alternatives in patients with documented SLCO1B1 c.521T>C variant. Option A: The SLCO1B1 variant is a loss-of-function, not a gain-of-function, mutation. The mechanism described -- skeletal muscle CYP3A4 upregulation producing toxic oxidation products -- is not an established mechanism of statin myopathy. This option misidentifies the variant type and fabricates the myopathy mechanism. Option B: SLCO1B1 encodes OATP1B1, a hepatic influx transporter -- not a CYP2C9 enzyme in the intestinal wall. The SLCO1B1 variant does not reduce CYP2C9 activity. This option incorrectly identifies the gene product and the mechanism. Option C: OATP1B1 is a sinusoidal hepatic influx transporter, not a bile acid transporter involved in enterohepatic recirculation. The mechanism described is pharmacologically incorrect; the variant's clinical significance lies in impaired sinusoidal uptake from portal blood, not in bile acid recycling. Option D: The SLCO1B1 variant affects the OATP1B1 hepatic influx transporter -- it does not reduce CYP3A4 expression. SLCO1B1 is on chromosome 12; CYP3A4 is on chromosome 7. These are distinct genes with distinct functions. This option conflates transporter pharmacogenomics with metabolic enzyme pharmacogenomics. Option E: Correct. The SLCO1B1 c.521T>C variant is a loss-of-function polymorphism reducing OATP1B1 hepatic uptake of statin acids; impaired hepatic extraction leaves more statin in systemic circulation, increasing skeletal muscle exposure and myopathy risk. Simvastatin is most affected; rosuvastatin and pravastatin are least affected due to lower OATP1B1 dependence.

ANSWER: B

Rationale:

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol classifies statin regimens into three intensity tiers based on the expected percentage reduction in LDL-C from an individual's untreated baseline. High-intensity statin therapy is defined as regimens expected to reduce LDL-C by 50% or more. The two qualifying regimens are atorvastatin 40 mg daily (expected approximately 49-50% LDL-C reduction) and atorvastatin 80 mg daily (expected approximately 50-60% reduction), and rosuvastatin 20 mg daily (expected approximately 52% reduction) and rosuvastatin 40 mg daily (expected approximately 55-63% reduction). No other statin at any approved dose consistently achieves the 50% or greater threshold. Moderate-intensity statin therapy achieves 30-49% LDL-C reduction (examples: atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg). This classification is based on percentage reduction from untreated baseline, not on achieving a specific absolute LDL-C target -- a distinction that matters because patients with very high baseline LDL-C may need add-on therapy even on high-intensity statins to reach recommended targets. Option A: The definition of 30% or more LDL-C reduction corresponds to moderate-intensity, not high-intensity, statin therapy. The agents and doses listed fall within the moderate-intensity tier. CYP3A4 genotyping and baseline transaminase levels are not the basis for high-intensity statin classification. Option B: Correct. High-intensity statin therapy per ACC/AHA 2018 is defined as 50% or greater LDL-C reduction from untreated baseline, achieved by atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily. Option C: High-intensity statin classification is based on percentage LDL-C reduction from baseline, not on achieving an absolute LDL-C below 70 mg/dL. Rosuvastatin 40 mg does not carry a black-box warning limiting its use to patients who have failed atorvastatin 80 mg -- this is factually incorrect. Option D: The greater than 60% LDL-C reduction threshold is not part of the ACC/AHA intensity classification. Atorvastatin 80 mg and rosuvastatin 40 mg are both classified as high-intensity regimens. The upper-moderate versus high-intensity distinction described does not correspond to any current guideline classification. Option E: High-intensity statin classification is an ACC/AHA guideline concept, not an FDA labeling designation. FDA labels do not use the high-intensity/moderate-intensity/low-intensity framework -- that language is entirely a guideline construct. The regimens listed span the full range of intensities, not a high-intensity-only category.

ANSWER: A

Rationale:

Statins improve eNOS (endothelial nitric oxide synthase) expression and activity through a mechanism that is rapid, independent of LDL-C lowering, and operates via the same isoprenoid depletion pathway responsible for anti-inflammatory pleiotropic effects. HMG-CoA reductase inhibition reduces geranylgeranyl pyrophosphate (GGPP) concentrations, impairing prenylation of RhoA GTPase. In endothelial cells, membrane-anchored RhoA normally activates Rho kinase (ROCK), which phosphorylates eNOS mRNA-binding proteins and destabilizes eNOS mRNA, reducing eNOS expression and nitric oxide production. When RhoA prenylation is impaired by GGPP depletion, RhoA remains cytosolic and inactive -- relieving ROCK-mediated eNOS mRNA destabilization. The resulting increase in eNOS expression and activity elevates nitric oxide production, improving endothelium-dependent vasodilation and reducing endothelial expression of adhesion molecules. This effect is detectable within 24-72 hours of statin initiation in cell culture and in human studies measuring flow-mediated dilation -- well before LDL-C reduction of any magnitude occurs -- consistent with the early separation of event curves observed in ACS statin trials. Option A: Correct. GGPP depletion impairs RhoA prenylation, reducing ROCK-mediated eNOS mRNA destabilization; increased eNOS expression and nitric oxide production improve endothelial function within days of statin initiation, independently of LDL-C changes. Option B: Statins do not directly bind or activate soluble guanylate cyclase (sGC). The sGC heme domain is activated by nitric oxide itself -- not by statin molecules. Any statin-mediated increase in cGMP is indirect, through increased eNOS-derived NO production, not through direct sGC binding. Option C: This option is incorrect in its timing claim. eNOS upregulation by statins through the RhoA/GGPP pathway is detectable within 24-72 hours -- it does not require 2-3 weeks of LDL-C lowering to precede it. The rapid endothelial improvement with statins is a direct pleiotropic effect preceding LDL-C change. Option D: KLF2 (Kruppel-like factor 2) upregulation by statins through Rho kinase inhibition is pharmacologically real. However, the claim that both the KLF2 and the RhoA/eNOS pathways require 3-4 weeks before any measurable change in nitric oxide production is detectable directly contradicts established evidence that statin-induced eNOS upregulation is measurable within days. Option E: Atorvastatin 80 mg does not achieve maximum LDL receptor upregulation and peak LDL-C reduction within 48-72 hours -- maximal LDL-C reduction requires approximately 2-4 weeks of continuous therapy. The early ACS event curve separation at 30 days is not explained by completed LDL-C lowering within 48-72 hours of the first dose.

ANSWER: D

Rationale:

The Scandinavian Simvastatin Survival Study (4S) is the landmark randomized controlled trial that established statin therapy as the standard of care in secondary prevention. The trial enrolled 4,444 patients -- men and women -- with a history of angina pectoris or prior myocardial infarction and elevated total cholesterol between 5.5 and 8.0 mmol/L (213-309 mg/dL). Patients were randomized to simvastatin (titrated to 20-40 mg daily) or placebo and followed for a median of 5.4 years. All-cause mortality was reduced by approximately 30% in the simvastatin arm (relative risk 0.70). Major coronary events were reduced by approximately 34%. Published in The Lancet in 1994, 4S was the first large randomized placebo-controlled trial to demonstrate that a lipid-lowering drug reduces total mortality -- a finding that overcame prevailing skepticism about whether cholesterol lowering could translate into survival benefit. The trial's enrollment criteria and its mortality endpoint remain the historical foundation on which subsequent statin outcome trials were built. Option A: The PROVE IT-TIMI 22 trial enrolled patients with acute coronary syndrome and compared atorvastatin 80 mg to pravastatin 40 mg -- it was not a placebo-controlled simvastatin mortality trial and enrolled patients with ACS rather than stable secondary prevention patients. Its contribution was establishing the superiority of high-intensity over moderate-intensity statin therapy in ACS, not the first demonstration of statin mortality benefit. Option B: The Heart Protection Study (HPS) enrolled 20,536 patients -- not 4,444. HPS did demonstrate a reduction in all-cause mortality. The claim that HPS did not show an all-cause mortality reduction is factually incorrect. Option C: JUPITER enrolled patients with low LDL-C and elevated hsCRP -- it was a primary prevention trial using rosuvastatin, not a secondary prevention trial with prior myocardial infarction using simvastatin. The enrollment number 4,444 correctly describes 4S, not JUPITER, which enrolled 17,802 participants. Option D: Correct. The 4S trial enrolled 4,444 secondary prevention patients with elevated total cholesterol, demonstrated approximately 30% reduction in all-cause mortality with simvastatin over 5.4 years, and was the first large randomized trial to establish a survival benefit with lipid-lowering therapy. Option E: The TNT trial enrolled 10,001 patients -- not 4,444 -- and compared atorvastatin 80 mg to atorvastatin 10 mg, not simvastatin versus placebo. TNT's contribution was demonstrating incremental benefit of high-intensity over moderate-intensity atorvastatin in stable secondary prevention, not establishing the first statin mortality benefit against placebo.

ANSWER: C

Rationale:

Amiodarone and its primary active metabolite desethylamiodarone are clinically significant inhibitors of CYP3A4. Simvastatin is an inactive lactone prodrug converted to simvastatin acid (the active HMG-CoA reductase inhibitor) by esterases, and simvastatin acid and its metabolites are subsequently oxidized by CYP3A4. When CYP3A4 is inhibited by amiodarone, simvastatin acid plasma concentrations rise substantially, increasing systemic statin exposure and passive diffusion into skeletal muscle. The FDA prescribing information for simvastatin carries a specific dose limitation: simvastatin should not exceed 20 mg daily in patients taking amiodarone, based on the increased risk of myopathy and rhabdomyolysis with higher doses in the presence of CYP3A4 inhibition. This patient was on simvastatin 40 mg -- above the FDA-specified limit for concurrent amiodarone use -- and has developed myopathy (proximal weakness, CK greater than 20 times the upper limit of normal), consistent with statin-associated myopathy from this drug interaction. The appropriate management is to discontinue simvastatin and transition to a statin that does not rely on CYP3A4 -- rosuvastatin (minimal CYP metabolism, primarily OATP1B1-mediated hepatic uptake) or pravastatin (also minimally CYP-dependent) are the appropriate alternatives. Option A: Amiodarone is a CYP3A4 inhibitor, not an inducer. CYP3A4 induction would accelerate simvastatin metabolism and reduce -- not increase -- plasma concentrations. Amiodarone does not cause skeletal muscle damage through potassium channel blockade; sarcolemmal damage from potassium channel blockade is not an established mechanism of amiodarone skeletal muscle toxicity. Option B: Amiodarone is not a clinically significant P-glycoprotein inhibitor in the context of simvastatin biliary elimination. Simvastatin's plasma half-life does not increase to 48 hours with amiodarone co-administration. The mechanism of the interaction is CYP3A4 inhibition, not ABCB1-mediated biliary elimination competition. Furthermore, in a patient who has already developed myopathy with CK greater than 20 times normal, simple dose reduction is insufficient -- simvastatin should be fully discontinued. Option C: Correct. Amiodarone inhibits CYP3A4, raising simvastatin acid concentrations and increasing skeletal muscle exposure. The FDA label limits simvastatin to 20 mg daily with amiodarone. This patient on simvastatin 40 mg with amiodarone has developed myopathy consistent with this interaction; switching to rosuvastatin or pravastatin is the appropriate management. Option D: Simvastatin is metabolized primarily by CYP3A4 -- not CYP2C9. Fluvastatin is the statin predominantly metabolized by CYP2C9. Switching to fluvastatin in the context of amiodarone use is not pharmacologically sound, as amiodarone also has some CYP2C9 inhibitory activity. The framing of fluvastatin as safe at "lower myopathic potency" does not constitute sound clinical rationale for drug selection in established myopathy. Option E: While amiodarone does have some OATP1B1 inhibitory activity, the dominant and clinically established mechanism of the simvastatin-amiodarone interaction is CYP3A4 inhibition, not OATP1B1 blockade. Adding ezetimibe and reducing simvastatin to 10 mg in a patient with CK greater than 20 times normal is insufficient management -- simvastatin should be discontinued and fully cleared before any rechallenge is considered.

ANSWER: E

Rationale:

The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease who were on optimized background statin therapy. Critically, all enrolled patients were already receiving the maximum tolerated statin dose, and the mean LDL-C in the placebo arm was 92 mg/dL -- directly mirroring this patient's clinical situation and confirming that a substantial proportion of very high-risk secondary prevention patients remain above LDL-C targets despite optimal statin therapy. Adding evolocumab (a PCSK9 inhibitor) reduced median LDL-C from 92 mg/dL to approximately 30 mg/dL and reduced the primary composite cardiovascular endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% over a median 26-month follow-up. The key pharmacological principle reinforced by FOURIER is the lower-is-better principle: consistent with the CTT meta-analysis framework, further LDL-C reduction from 92 mg/dL to 30 mg/dL produced additional proportional event reduction, with no observed safety threshold below which LDL-C lowering ceased to be beneficial in this follow-up period. For this patient -- with LDL-C of 91 mg/dL on maximum statin plus ezetimibe -- the FOURIER data directly support adding a PCSK9 inhibitor as the next intensification step. Option A: The FOURIER trial did not establish 70 mg/dL as a physiological lower limit for beneficial LDL-C reduction -- on the contrary, it demonstrated meaningful event reduction with LDL-C lowered to approximately 30 mg/dL. The lower-is-better principle was reinforced, not refuted, by FOURIER. No safety threshold below 70 mg/dL was identified. Option B: FOURIER did not require LDL-C above 150 mg/dL at entry -- enrollment required LDL-C of 70 mg/dL or greater (or non-HDL-C of 100 mg/dL or greater) despite statin therapy, and the mean baseline LDL-C was 92 mg/dL. The claim that no significant benefit was observed in patients below 100 mg/dL is incorrect; benefit was observed across the LDL-C range enrolled. Option C: The FOURIER trial demonstrated a statistically significant 15% reduction in the primary composite endpoint with evolocumab versus placebo -- it did not show that add-on evolocumab provided no significant event reduction. The conclusion that statin intensification is preferable to PCSK9 inhibition in patients not yet at target misrepresents FOURIER's findings. Option D: FOURIER did not exclude patients with LDL-C below 100 mg/dL -- the trial enrolled patients across a range of LDL-C values above the guideline threshold, with the mean enrollment LDL-C of 92 mg/dL. The claim that FOURIER is irrelevant to patients below 100 mg/dL is factually incorrect. Option E: Correct. FOURIER enrolled 27,564 established ASCVD patients on optimized background statin, demonstrated a mean placebo-arm LDL-C of 92 mg/dL (confirming statin inadequacy in high-risk patients), and showed that evolocumab reduced LDL-C to approximately 30 mg/dL with a 15% reduction in the primary composite endpoint -- reinforcing the lower-is-better principle and supporting PCSK9 inhibitor add-on in patients above target despite maximally tolerated statin therapy.

ANSWER: B

Rationale:

The Heart Protection Study (HPS) is the landmark trial that most directly refutes the argument that statin benefit requires a baseline LDL-C above a specific threshold. HPS enrolled 20,536 patients with established vascular disease (prior MI, stroke, or peripheral artery disease) or high-risk conditions (diabetes, treated hypertension) and randomized them to simvastatin 40 mg or placebo. Crucially, there was no minimum LDL-C inclusion criterion -- patients were enrolled based on cardiovascular risk category rather than lipid levels. The trial demonstrated that simvastatin reduced major vascular events (non-fatal MI, coronary death, stroke, and revascularization) by approximately 24% across all baseline LDL-C subgroups, including patients with baseline LDL-C below 116 mg/dL (3.0 mmol/L) -- a subgroup that would conventionally be considered to have "normal" LDL-C and might not have received statin therapy under prior guidelines. This finding established the principle that cardiovascular risk category -- not pre-treatment LDL-C level -- determines whether statin therapy provides meaningful event reduction. Applied to this patient with diabetes and hypertension (both independent cardiovascular risk factors), the HPS data strongly support statin therapy regardless of the "normal" LDL-C level. Option A: PROVE IT-TIMI 22 enrolled ACS patients and compared high-intensity versus moderate-intensity statin therapy -- it was not designed to evaluate whether statin benefit varies by baseline LDL-C level. The claim that benefit was restricted to patients with baseline LDL-C above 130 mg/dL is a misrepresentation of PROVE IT's design and findings. Option B: Correct. The Heart Protection Study demonstrated that simvastatin 40 mg reduced major vascular events by approximately 24% regardless of baseline LDL-C level -- including patients with LDL-C below 116 mg/dL -- establishing cardiovascular risk category rather than pre-treatment LDL-C as the determinant of statin benefit. Option C: The 4S trial did enroll patients with total cholesterol between 5.5 and 8.0 mmol/L, but it did not demonstrate that benefit was restricted to the upper end of this range. The trial was not designed or powered to test whether benefit varied across the baseline cholesterol subrange enrolled, and it did not establish a lower cholesterol threshold below which benefit disappears. Option D: JUPITER enrolled patients based on LDL-C below 130 mg/dL and elevated hsCRP -- its post-hoc analyses do not clearly attribute all benefit to LDL-C lowering versus anti-inflammatory effects, and the relative contributions remain debated. JUPITER does not establish LDL-C level as the "true determinant" of statin response; that interpretation misrepresents the ongoing debate about JUPITER's mechanistic conclusions. Option E: The TNT trial compared atorvastatin 80 mg versus 10 mg in stable coronary disease patients -- it did not identify a lower LDL-C threshold below which further intensification provides no benefit. TNT demonstrated that high-intensity therapy produced incremental event reduction compared to moderate-intensity across the enrolled population, not diminishing returns at lower baseline LDL-C.

ANSWER: B

Rationale:

The pharmacokinetic rationale for rosuvastatin in alternate-day dosing rests on two properties. First, rosuvastatin has a plasma half-life of approximately 19 hours -- substantially longer than simvastatin (approximately 2 hours) or pravastatin (approximately 2-3 hours) -- meaning that drug concentrations decline more slowly between doses, providing more sustained hepatic exposure with less complete washout on off-days. Second, rosuvastatin's high hepatoselectivity -- mediated through active OATP1B1 uptake concentrating the drug in hepatocytes -- means that the drug achieves high intrahepatic concentrations relative to systemic plasma concentrations. The consequent LDL receptor upregulation persists beyond the plasma concentration half-life, extending pharmacodynamic effect between doses. Together, these properties make rosuvastatin more suitable for non-daily dosing than short-half-life statins. Clinical evidence from multiple small trials supports that rosuvastatin at 5-10 mg two to three times weekly achieves LDL-C reductions of approximately 20-30% from untreated baseline in patients unable to tolerate daily dosing. When combined with daily ezetimibe -- which inhibits intestinal cholesterol absorption through the completely independent NPC1L1 (Niemann-Pick C1-Like 1 protein) mechanism -- the combination achieves LDL-C reductions of 40-50%, comparable to moderate-intensity daily statin monotherapy, while maintaining tolerability. Option A: Rosuvastatin does not undergo enterohepatic recirculation to a clinically meaningful degree. Statins are not recirculated in bile in a manner that provides continuous hepatic re-exposure between doses. This mechanism is pharmacologically fabricated. Option B: Correct. Rosuvastatin's approximately 19-hour half-life and high hepatoselectivity provide pharmacokinetic advantages for non-daily dosing, with 2-3 times weekly administration achieving approximately 20-30% LDL-C reduction, and the combination with daily ezetimibe achieving 40-50% reduction comparable to moderate-intensity daily statin therapy. Option C: Rosuvastatin is not a prodrug -- it is administered as the active acid form and does not require hepatic activation. Simvastatin is the statin administered as an inactive lactone prodrug. This option incorrectly attributes a prodrug mechanism to rosuvastatin. Option D: While rosuvastatin's hydrophilicity reduces passive diffusion into skeletal muscle relative to lipophilic statins, it is not correct that rosuvastatin produces no measurable skeletal muscle concentrations. More importantly, rosuvastatin is not universally safe in all statin-intolerant patients regardless of dose or frequency -- it can produce statin-associated muscle symptoms, particularly in patients with the SLCO1B1 variant or at higher doses. The "universal safety" claim overstates the evidence. Option E: Rosuvastatin is not available in an extended-release formulation -- it is a conventional immediate-release tablet. The pharmacological rationale for alternate-day dosing is pharmacokinetic (long half-life, persistent LDL receptor upregulation), not formulation-based. This option describes a product characteristic that does not exist.

ANSWER: C

Rationale:

When a patient on maximally tolerated high-intensity statin therapy has not reached their LDL-C target, adding an agent with an independent mechanism is the pharmacologically correct next step -- and ezetimibe is the first-line choice for this intensification. Ezetimibe inhibits NPC1L1 (Niemann-Pick C1-Like 1 protein), the intestinal brush border transporter responsible for cholesterol absorption from the gut lumen into enterocytes. By reducing intestinal cholesterol absorption, ezetimibe decreases cholesterol delivery to the liver, further depleting intracellular free cholesterol and amplifying the statin-initiated SREBP-2 response -- further upregulating LDL receptor expression beyond what statin alone achieves. This mechanism is completely independent of HMG-CoA reductase inhibition. Ezetimibe typically achieves an additional 15-20% LDL-C reduction additive to background statin therapy. The statin dose escalation alternative is constrained by the rule of 6s: atorvastatin is already at maximum dose (80 mg), so no further dose escalation is possible; even if it were, each dose doubling yields only approximately 6% additional LDL-C reduction due to the log-linear dose-response curve and PCSK9 counter-regulation. Ezetimibe therefore provides two to three times more incremental LDL-C reduction than any achievable statin dose escalation and does so through a pharmacologically additive, non-overlapping mechanism. Option A: While rosuvastatin is more potent per milligram than atorvastatin, the difference in achievable LDL-C reduction between atorvastatin 80 mg and rosuvastatin 40 mg is modest (approximately 5-10 percentage points at most) -- far less than the 15-20% incremental reduction achievable with ezetimibe. Switching statins is not the pharmacologically most efficient strategy when maximum statin intensity has already been achieved and an independent mechanism is available. Option B: Bile acid sequestrants (colesevelam, cholestyramine, colestipol) achieve LDL-C reductions of approximately 15-30% additive to statin therapy -- not 35-40%. More importantly, bile acid sequestrants can raise triglyceride levels, are associated with significant gastrointestinal tolerability issues, and are less convenient than ezetimibe. They are appropriate alternatives when ezetimibe is not tolerated, not the pharmacologically most efficient first-line add-on choice. Option C: Correct. Ezetimibe's NPC1L1-mediated inhibition of intestinal cholesterol absorption provides an independent mechanism that amplifies SREBP-2-mediated LDL receptor upregulation, achieving an additional 15-20% LDL-C reduction additive to maximum statin therapy -- substantially more efficient than any achievable statin dose escalation constrained by the log-linear dose-response plateau. Option D: Niacin was not demonstrated to reduce cardiovascular events when added to statin therapy in the HPS2-THRIVE trial -- on the contrary, HPS2-THRIVE showed no significant cardiovascular benefit from extended-release niacin/laropiprant added to statin therapy, and the combination was associated with increased serious adverse events. This option misrepresents the HPS2-THRIVE findings, which effectively ended routine clinical use of niacin for cardiovascular risk reduction in patients already on statin therapy. Option E: Fenofibrate activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), which primarily reduces triglycerides and raises HDL-C by increasing lipoprotein lipase expression and reducing apoC-III. Fenofibrate does not directly upregulate LDL receptor transcription through a SREBP-2-independent pathway in a manner that achieves 25-35% additive LDL-C reduction when added to high-intensity statin therapy. Fibrates are indicated for severe hypertriglyceridemia, not as the primary LDL-C-lowering add-on strategy in statin-treated patients.

ANSWER: C

Rationale:

In all patients presenting with ACS -- including STEMI -- current ACC/AHA guidelines recommend initiating or continuing high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) within 24 hours of presentation, regardless of baseline LDL-C level. The indication for statin therapy in this setting is categorical: ACS constitutes established ASCVD, placing the patient in the very high-risk category for which high-intensity statin therapy is recommended irrespective of the LDL-C value. The admission LDL-C of 74 mg/dL does not modify this recommendation. It is also important to recognize that acute MI predictably lowers LDL-C by 15-20 mg/dL below true baseline due to the acute-phase response -- meaning this patient's true untreated baseline LDL-C is likely higher than 74 mg/dL. More fundamentally, even if baseline LDL-C were genuinely below 70 mg/dL, the PROVE IT-TIMI 22 evidence base supports high-intensity statin initiation in all ACS patients: the trial enrolled patients across a range of baseline LDL-C values and demonstrated benefit regardless of entry LDL-C. The early pleiotropic benefits -- Rho GTPase-mediated anti-inflammatory effects, eNOS upregulation, plaque-stabilizing macrophage suppression -- operate within days of initiation, independent of any LDL-C change, and contribute to the early event curve separation seen at 30 days. Option A: While acute MI does transiently lower LDL-C below true baseline, this is not a rationale for deferring statin initiation. The recommendation to initiate high-intensity statin therapy in ACS is not conditional on confirming a high "true baseline" LDL-C -- it is based on the patient's risk category and the established early pleiotropic and long-term LDL-C-lowering benefits of statin therapy in all ACS patients. Option B: ACC/AHA guidelines do not require an LDL-C of at least 70 mg/dL before recommending high-intensity statin therapy in ACS. The recommendation is risk-category-driven, not LDL-C-threshold-driven, in established ASCVD. No PROVE IT-TIMI 22 subgroup analysis established a lower LDL-C threshold below which ACS patients derive no benefit from high-intensity statin initiation. Option C: Correct. High-intensity statin therapy should be initiated within 24 hours of ACS presentation regardless of baseline LDL-C level, driven by the patient's risk category and the early pleiotropic benefits of high-intensity statins in the acute coronary syndrome setting. Option D: Moderate-intensity statin therapy is not the appropriate initial regimen for an ACS patient. PROVE IT-TIMI 22 established that high-intensity atorvastatin is superior to moderate-intensity pravastatin in ACS; current guidelines reflect this evidence with a categorical recommendation for high-intensity therapy in ACS regardless of LDL-C level. There is no LDL-C threshold below 100 mg/dL that changes this recommendation to moderate-intensity. Option E: Routine pharmacogenomic screening for SLCO1B1 variants is not required before initiating statin therapy in ACS. While SLCO1B1 pharmacogenomics are clinically relevant for patients with recurrent myopathy on multiple statins, the risk-benefit calculation in ACS strongly favors immediate high-intensity statin initiation -- the cardiovascular benefit in the first 30 days far outweighs the risk of myopathy, which is manageable through monitoring.

ANSWER: E

Rationale:

Statin-associated muscle symptoms (SAMS) with normal CK -- the pattern described here -- are the most common form of statin intolerance and affect approximately 5-10% of patients in clinical practice (higher rates in observational studies than in randomized controlled trials, partly due to nocebo effects). Critically, normal CK in the setting of myalgia does not confirm irreversible muscle injury or predict rhabdomyolysis with rechallenge -- it simply indicates that myofibrillar damage has not reached the threshold of CK release. The appropriate response to SAMS with normal CK is not complete statin abandonment but systematic rechallenge management. The first step is switching to a statin with lower skeletal muscle penetrance: rosuvastatin and pravastatin, both hydrophilic agents, have lower rates of passive diffusion into skeletal muscle compared with lipophilic statins (atorvastatin, simvastatin, lovastatin) and are associated with lower SAMS rates in statin-intolerant patients. Starting at a low dose or alternate-day schedule further reduces peak muscle exposure. Multiple studies demonstrate that the majority of patients with SAMS on one statin can tolerate a different statin at a lower dose or alternate-day frequency. For patients who cannot tolerate any daily statin, alternate-day rosuvastatin (5-10 mg two to three times weekly) combined with daily ezetimibe achieves 40-50% LDL-C reduction -- comparable to moderate-intensity daily statin therapy -- and represents a clinically meaningful strategy that preserves cardiovascular risk reduction. Complete discontinuation in a patient with 13% 10-year ASCVD risk sacrifices substantial event reduction and should not be the default outcome after a single statin trial at a single dose. Option A: Normal CK in the setting of myalgia does not confirm pre-rhabdomyolytic injury detectable only by biopsy. Statin-associated myalgia with normal CK is a well-characterized clinical entity that frequently resolves with agent substitution or dose reduction and does not uniformly progress to rhabdomyolysis with rechallenge. The claim that normal-CK SAMS is a contraindication to rechallenge is not supported by evidence or guideline recommendations. Option B: While nocebo effects do contribute meaningfully to reported SAMS -- as demonstrated by blinded rechallenge studies showing high rates of symptom resolution when patients do not know they are receiving statin -- it is not accurate that symptoms with normal CK have no pharmacological basis and require no management change. SAMS with normal CK can have genuine pharmacological causes, and the appropriate response is agent substitution and rechallenge, not reassurance and continuation of the same drug that caused symptoms. Option C: PCSK9 inhibitor monotherapy without prior statin rechallenge attempts is not the standard guideline recommendation for a first episode of SAMS with normal CK. Both evolocumab and alirocumab are FDA-approved for patients with established ASCVD or familial hypercholesterolemia who require additional LDL-C lowering -- but the labeled indications do not bypass the expectation of statin optimization before PCSK9 inhibitor initiation in most patients. Cost, access, and insurance criteria also typically require documented statin intolerance after multiple trials. Option D: Colesevelam achieves LDL-C reductions of approximately 15-18% as monotherapy -- not 40-45%. The claim that colesevelam fully substitutes for high-intensity statin therapy in cardiovascular risk reduction is not supported by outcomes trial evidence; no bile acid sequestrant monotherapy trial has demonstrated mortality benefit comparable to statin therapy. Option E: Correct. Complete statin discontinuation after a single trial with SAMS and normal CK is not the appropriate endpoint; systematic rechallenge with a hydrophilic statin (rosuvastatin or pravastatin) at low dose or alternate-day frequency is the recommended approach, with the option of alternate-day rosuvastatin plus daily ezetimibe achieving 40-50% LDL-C reduction if daily statin remains intolerable.

ANSWER: B

Rationale:

Cyclosporine is a potent inhibitor of both CYP3A4 and the hepatic influx transporter OATP1B1. Statins that are substrates of either or both of these pathways experience substantially elevated plasma concentrations when cyclosporine is co-administered, dramatically increasing the risk of statin-associated myopathy and rhabdomyolysis. Among commonly used statins, the hierarchy of interaction severity with cyclosporine broadly follows CYP3A4 and OATP1B1 dependence: simvastatin and lovastatin (highly CYP3A4-dependent, prodrug forms requiring hydrolysis) carry the highest risk; atorvastatin and rosuvastatin carry intermediate risk due to OATP1B1 dependence; pravastatin carries the lowest risk because it undergoes minimal CYP metabolism and has lower OATP1B1 dependence relative to other statins. Clinical pharmacokinetic studies confirm that pravastatin shows the lowest relative increase in AUC when combined with cyclosporine compared with simvastatin, lovastatin, and atorvastatin. Pravastatin is therefore the preferred statin in cyclosporine-treated transplant recipients, though even pravastatin doses should be limited (typically to 20 mg daily or less) given residual interaction potential and the high immunosuppressive burden in this population. Option A: Atorvastatin is not a CYP3A4 inducer -- it is a CYP3A4 substrate. No statin induces its own metabolism through CYP3A4 autoinduction; that mechanism is characteristic of drugs such as carbamazepine and rifampin. This option describes a pharmacological mechanism that does not exist for atorvastatin. Option B: Correct. Pravastatin's minimal CYP-mediated metabolism and lower OATP1B1 dependence confer the least pharmacokinetic interaction risk with cyclosporine among commonly used statins; it is the preferred statin in cyclosporine-treated transplant recipients, with doses limited to the lowest effective amount given residual interaction potential. Option C: Simvastatin's high first-pass hepatic extraction does not protect against cyclosporine-mediated drug interactions -- on the contrary, cyclosporine's OATP1B1 inhibition impairs the hepatic uptake that drives that first-pass extraction, paradoxically increasing simvastatin systemic concentrations. Simvastatin carries the highest myopathy risk of any statin in combination with cyclosporine and is contraindicated in this combination at standard doses. Option D: Rosuvastatin is not a CYP3A4 inhibitor -- it has minimal CYP3A4 interaction. The mechanism described (competitive protection of its own metabolism through CYP3A4 inhibition) is pharmacologically fabricated. Rosuvastatin's interaction with cyclosporine is primarily through OATP1B1 inhibition, which does raise rosuvastatin plasma concentrations and increases myopathy risk. Option E: Fluvastatin is not actively exported via MRP2 in a manner that creates a self-protective hepatoselectivity. The described mechanism -- cyclosporine-mediated MRP2 inhibition paradoxically increasing intrahepatic fluvastatin while reducing systemic exposure -- is not an established pharmacological interaction and does not reflect known fluvastatin disposition.

ANSWER: C

Rationale:

The pleiotropic effects of statins -- anti-inflammatory activity mediated through Rho GTPase prenylation inhibition, improved endothelial nitric oxide synthase (eNOS) expression, antithrombotic effects, and plaque-stabilizing macrophage activity -- are pharmacologically real and well-characterized. They are detectable in human subjects at clinical statin doses, contribute to the rapid early benefits seen in ACS trials, and likely play a role in the cardiovascular event reduction observed in trials such as JUPITER. The critical caveat, however, is that the independent contribution of pleiotropic effects to cardiovascular event reduction -- separate from LDL-C lowering -- has not been quantified with sufficient precision to justify using them as a rationale for selecting a lower-potency statin regimen. The CTT Collaboration meta-analysis, pooling 26 trials and approximately 169,000 participants, demonstrates that cardiovascular event reduction scales precisely and proportionally with LDL-C lowering (22% per mmol/L) across all statins, all doses, and all patient populations -- consistent with LDL-C reduction being the dominant driver of benefit. No rigorous evidence supports the conclusion that a statin with greater pleiotropic activity at lower dose reduces cardiovascular events more than a higher-potency statin achieving greater LDL-C reduction. Pleiotropic effects almost certainly contribute at the margins -- particularly in ACS and inflammatory settings -- but invoking them to justify subtherapeutic dosing or selection of a lower-potency regimen over a higher-potency alternative is not clinically defensible. Option A: Pleiotropic effects are pharmacologically real and have been demonstrated in human subjects. Statin-induced reductions in hsCRP, ICAM-1, and other inflammatory markers occur at clinical doses and are reproducible. The claim that all inflammatory effects are secondary to LDL-C lowering is contradicted by the timing of these effects (occurring days before meaningful LDL-C reduction) and by mechanistic studies of Rho GTPase prenylation inhibition. Option B: The independent contribution of pleiotropic effects to cardiovascular event reduction has not been conclusively quantified -- this is precisely the clinical uncertainty that limits their use as a selection criterion. Furthermore, pleiotropic effects through GGPP depletion and Rho GTPase pathway inhibition are not necessarily maximal at low statin doses in all patients -- the dose-response relationship for isoprenoid depletion is not fully characterized in this manner. Option C: Correct. Pleiotropic effects are pharmacologically real but their independent cardiovascular benefit is not quantified to a degree that justifies preferring a lower-potency regimen over one achieving greater LDL-C reduction; the CTT meta-analysis confirms that LDL-C lowering is the dominant driver of proportional event reduction. Option D: The claim that Rho GTPase prenylation is fully saturated at the minimum effective statin dose -- so that no additional pleiotropic benefit accrues at higher doses -- is not established in the clinical pharmacology literature. The dose-response relationship for isoprenoid depletion and Rho GTPase prenylation inhibition across the clinical dose range has not been characterized with sufficient precision to support this claim. Option E: Revascularization does not eliminate vulnerable plaque throughout the coronary tree -- it treats the culprit lesion, leaving non-culprit atherosclerotic plaques throughout the vasculature that remain vulnerable to rupture. Pleiotropic stabilization of non-culprit plaques remains biologically relevant in secondary prevention patients. The claim that revascularization eliminates the substrate for pleiotropic activity is clinically incorrect.